26 results on '"Caméléna F"'
Search Results
2. Infections caused by Tissierella praeacuta: A report of two cases and literature review
- Author
-
Caméléna, F., Pilmis, B., Mollo, B., Hadj, A., Le Monnier, A., and Mizrahi, A.
- Published
- 2016
- Full Text
- View/download PDF
3. Caractérisation génotypique des souches de bactéries hautement résistantes émergentes (BHRE), une étude descriptive dans deux hôpitaux universitaires français
- Author
-
Uzuriaga, M., primary, Vigouroux, A., additional, Fernandes, P., additional, Liberge, M, additional, Mathar, M., additional, Braille, A., additional, Merimèche, M., additional, Poncin, T., additional, Caméléna, F., additional, and Berçot, B., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Symphysites bactériennes, une entité rare et de diagnostic difficile : étude rétrospective sur 8 ans
- Author
-
Huriez, P., Goujon, A., Munier, A-L., Camelena, F., Flament, V., Molina, J-M., and Lafaurie, M.
- Published
- 2022
- Full Text
- View/download PDF
5. Prospective evaluation of the Alere i Influenza A&B nucleic acid amplification versus Xpert Flu/RSV
- Author
-
Nguyen Van, J.C., primary, Caméléna, F., additional, Dahoun, M., additional, Pilmis, B., additional, Mizrahi, A., additional, Lourtet, J., additional, Behillil, S., additional, Enouf, V., additional, and Le Monnier, A., additional
- Published
- 2016
- Full Text
- View/download PDF
6. Analyse du respect de la contre-indication digoxine-calcium i.v.
- Author
-
Camelena, F., Descout, J., Corlouer, C., and Édouard, B.
- Published
- 2012
- Full Text
- View/download PDF
7. Microbiological monitoring during antibiotic therapy in patients with ventilated acquired pneumonia: A proof-of-concept.
- Author
-
Dudoignon E, Schneider J, Caméléna F, de Tymowski C, and Dépret F
- Abstract
Competing Interests: Declaration of competing interest Emmanuel Dudoignon, Julia Schneider, Christian de Tymowski have no conflicts of interest to declare. Francois Camelena reports consulting fees Biomerieux. Francois Dépret reports consulting fees Sedana, biocartis and biomerieux and research grant French ministry of health and ESICM.
- Published
- 2025
- Full Text
- View/download PDF
8. Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023.
- Author
-
Caméléna F, Mérimèche M, Brousseau J, Mainardis M, Verger P, Le Risbé C, Brottet E, Thabuis A, Bébéar C, Molina JM, Lot F, Chazelle E, and Berçot B
- Subjects
- Adult, Female, Humans, Male, Azithromycin pharmacology, Azithromycin therapeutic use, Ceftriaxone pharmacology, Ceftriaxone therapeutic use, France epidemiology, Microbial Sensitivity Tests, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Drug Resistance, Multiple, Bacterial genetics, Gonorrhea drug therapy, Gonorrhea microbiology, Gonorrhea epidemiology, Neisseria gonorrhoeae drug effects, Neisseria gonorrhoeae genetics, Neisseria gonorrhoeae isolation & purification
- Abstract
Since 2022, Europe has had 4 cases of extensively drug-resistant Neisseria gonorrhoeae, sequence type 16406, that is resistant to ceftriaxone and highly resistant to azithromycin. We report 2 new cases from France in 2023 involving strains genetically related to the 4 cases from Europe as well as isolates from Cambodia.
- Published
- 2024
- Full Text
- View/download PDF
9. Shorter Versus Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia: Time for a Tailored Duration?
- Author
-
Dudoignon E, Caméléna F, de Tymowski C, Lafaurie M, and Dépret F
- Subjects
- Humans, Gram-Negative Bacteria drug effects, Time Factors, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Bacteremia drug therapy, Bacteremia microbiology, Gram-Negative Bacterial Infections drug therapy
- Abstract
Competing Interests: Potential conflicts of interest. F. D. reports consulting fees Sedana, biocartis, and biomerieux and research grant ministry of health; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events made to Robert Debre's association from Biomerieux; support for attending meetings and/or travel from Biomerieux. F. C. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events made to Robert Debre's association from Biomerieux; support for attending meetings and/or travel from Biomerieux. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
- Published
- 2024
- Full Text
- View/download PDF
10. Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.
- Author
-
Dudoignon E, Caméléna F, Lafaurie M, Deniau B, Chaussard M, Coutrot M, Guillemet L, Cupaciu A, Pharaboz A, Boutin L, Benyamina M, Chaouat M, Mimoun M, Merimèche M, Mebazaa A, Plaud B, Berçot B, Dépret F, and Mellon G
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Burns complications, Burns microbiology, Drug Therapy, Combination, Treatment Outcome, Aged, Cross Infection microbiology, Cross Infection drug therapy, Cross Infection epidemiology, Drug Resistance, Multiple, Bacterial genetics, beta-Lactamases genetics, Burn Units, Acinetobacter baumannii drug effects, Acinetobacter baumannii genetics, Acinetobacter baumannii isolation & purification, Acinetobacter Infections drug therapy, Acinetobacter Infections microbiology, Acinetobacter Infections epidemiology, Disease Outbreaks, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Azabicyclo Compounds therapeutic use, Azabicyclo Compounds pharmacology, Intensive Care Units, Sulbactam therapeutic use, Sulbactam pharmacology, Drug Combinations, Carbapenems pharmacology, Carbapenems therapeutic use, Ceftazidime therapeutic use, Ceftazidime pharmacology
- Abstract
We present our findings on interpatient transmission, epidemic control measures, and the outcomes of a series of ten critically ill burn patients who were either colonized or infected with carbapenem-resistant Acinetobacter baumannii (CRAB). None of the five infected patients achieved clinical cure, and all experienced relapses. Microbiological failure was observed in 40% of the infected patients. The isolated CRAB strains were found to carry bla
OXA-23 and armA resistance genes. Despite the lack of clinical cure, all five infected patients survived and were discharged from the Burn Intensive Care Unit., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
11. Detection of CTX-M-15 ESBL in XDR Haemophilus parainfluenzae from a urethral swab.
- Author
-
Caméléna F, Merimèche M, Liberge M, Maubaret C, Donay JL, Taha MK, Fouéré S, and Berçot B
- Subjects
- Phylogeny, Amino Acid Substitution, beta-Lactamases genetics, Haemophilus parainfluenzae genetics, Anti-Bacterial Agents pharmacology
- Abstract
Objectives: Haemophilus parainfluenzae is an opportunistic pathogen causing respiratory tract infection and sexually transmitted diseases. The emergence of multidrug resistance in this species is particularly worrisome, especially since the recent description of CTX-M-15 ESBL-producing isolates in Spain. The aim of this study was to characterize a CTX-M-15-producing H. parainfluenzae clinical isolate, HP01, obtained from a urethral swab., Methods: MICs were determined with gradient strips for this isolate. Hydrolysis assays were performed with the β LACTA test. Genomic DNA from HP01 was subjected to Illumina and Oxford Nanopore sequencing to investigate the genetic environment of blaCTX-M-15. Phylogenetic analysis was performed with available H. parainfluenzae genomes from the NCBI database, including CTX-M-15 producers., Results: HP01, an XDR isolate, was resistant to penicillin, third-generation cephalosporins, fluoroquinolones, macrolides, cyclines and co-trimoxazole and susceptible only to carbapenems and rifampicin. HP01 carried blaTEM-1, blaCTX-M-15, tet(M), catS and mef(E)/mel and harboured amino acid substitutions in PBP3, PBP5, GyrA, ParC and FolA implicated in resistance. Genomic analysis revealed that blaCTX-M-15 was carried by a Tn3-like transposon inserted into a novel integrative and conjugative element (ICE), ICEHpaSLS, present on the chromosome and belonging to the ICEHin1056 family described in Haemophilus influenzae. The tet(M)-MEGA element was also detected on the chromosome. No plasmid was found. The phylogenetic analysis showed that four H. parainfluenzae producing CTX-M-15 clustered in the same clade., Conclusions: Here we report the description of an XDR H. parainfluenzae producing blaCTX-M-15 isolated from a urethral swab. The blaCTX-M-15 gene was inserted into an ICE structure similar to those recently described in CTX-M-15 producers in Spain. The emergence of XDR H. parainfluenzae producing blaCTX-M-15 is a matter of great concern. Careful surveillance is required to prevent its spread., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
12. Performance evaluation of a PCR panel (FilmArray® Pneumonia Plus) for detection of respiratory bacterial pathogens in respiratory specimens: A systematic review and meta-analysis.
- Author
-
Moy AC, Kimmoun A, Merkling T, Berçot B, Caméléna F, Poncin T, Deniau B, Mebazaa A, Dudoignon E, and Dépret F
- Subjects
- Humans, Bacteria genetics, Multiplex Polymerase Chain Reaction methods, Pneumonia, Respiratory Tract Infections diagnosis, Respiratory Tract Infections microbiology, Bacterial Infections
- Abstract
Background: Accuracy and timing of antibiotic therapy remain a challenge for lower respiratory tract infections. New molecular techniques using Multiplex Polymerase Chain Reaction, including the FilmArray® Pneumonia Plus Panel [FAPP], have been developed to address this. The aim of this study is to evaluate the FAPP diagnostic performance for the detection of the 15 typical bacteria of the panel from respiratory samples in a meta-analysis from a systematic review., Methods: We searched PubMed and EMBASE from January 1, 2010, to December 31, 2022, and selected any study on the FAPP diagnostic performance on respiratory samples compared to the reference standard, bacterial culture. The main outcome was the overall diagnostic accuracy with sensitivity and specificity. We calculated the log Diagnostic Odds Ratio and analyzed performance for separate bacteria, antimicrobial resistance genes, and according to the sample type. We also reported the FAPP turnaround time and the out-of-panel bacteria number and species. This study is registered with PROSPERO (CRD42021226280)., Results: From 10 317 records, we identified 30 studies including 8 968 samples. Twenty-one were related to intensive care. The overall sensitivity and specificity were 94% [95% Confidence Interval (CI) 91-95] and 98% [95%CI 97-98], respectively. The log Diagnostic Odds Ratio was 6.35 [95%CI 6.05-6.65]. 9.3% [95%CI 9.2-9.5] of bacteria detected in culture were not included in the FAPP panel., Conclusion: This systematic review reporting the FAPP evaluation revealed a high accuracy. This test may represent an adjunct tool for pulmonary bacterial infection diagnostic and antimicrobial stewardship. Further evidence is needed to assess the impact on clinical outcome., (Copyright © 2023 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Two cases of extensively drug-resistant (XDR) Neisseria gonorrhoeae infection combining ceftriaxone-resistance and high-level azithromycin resistance, France, November 2022 and May 2023.
- Author
-
Maubaret C, Caméléna F, Mrimèche M, Braille A, Liberge M, Mainardis M, Guillaume C, Noel F, Bébéar C, Molina JM, Lot F, Chazelle E, and Berçot B
- Subjects
- Humans, Azithromycin pharmacology, France, Multilocus Sequence Typing, Neisseria gonorrhoeae genetics, Ceftriaxone pharmacology, Gonorrhea diagnosis, Gonorrhea drug therapy
- Abstract
We report two extensively drug-resistant (XDR) Neisseria gonorrhoeae (NG) isolates combining high-level resistance to azithromycin and resistance to ceftriaxone, obtained in France from two heterosexual patients, one of whom returned from Cambodia. Whole genome sequencing identified MLST ST16406, the mosaic penA -60.001 which caused ceftriaxone resistance in the internationally spreading FC428 clone, and the A2059G mutation in the 23S rRNA gene. The NG isolates F93 and F94 were related to XDR isolates detected in Austria and the United Kingdom in 2022.
- Published
- 2023
- Full Text
- View/download PDF
14. In vitro activity of apramycin against 16S-RMTase-producing Gram-negative isolates.
- Author
-
Caméléna F, Liberge M, Rezzoug I, Merimèche M, Naas T, and Berçot B
- Subjects
- RNA, Ribosomal, 16S genetics, Aminoglycosides pharmacology, Escherichia coli, Anti-Bacterial Agents pharmacology, Nebramycin pharmacology
- Abstract
Objectives: Apramycin is an aminoglycoside (AG) with a unique structure that is little affected by plasmid-mediated mechanisms of AG resistance, including most AG-modifying enzymes and 16S rRNA methyltransferases (16S-RMTases). We evaluate the activity of apramycin against a collection of 16S-RMTase-producing isolates, including Enterobacterales, non-fermenting bacteria, and carbapenemase producers., Methods: In total, 164 non-duplicate 16S-RMTase-producing isolates, including 84 Enterobacterales, 53 Acinetobacter baumannii and 27 Pseudomonas aeruginosa isolates, were included in the study. Whole-genome sequencing (WGS) was performed on all isolates with Illumina technology. The minimum inhibitory concentration (MIC) of apramycin was determined by broth microdilution with customized Sensititre plates (Thermo Fisher Scientific, Dardilly, France)., Results: We found that 95% (156/164) of the 16S-RMTase-producing isolates were susceptible to apramycin, with a MIC
50 of 4 mg/L and a MIC90 of 16 mg/L, respectively. Resistance rates were higher in P. aeruginosa (11%) than in A. baumannii (4%) or Enterobacterales (4%) (P < 0.0001 for each comparison). Eight isolates were resistant to apramycin, including one isolate with an MIC >64 mg/L due to the acquisition of the aac(3)-IV gene. The genetic environment of the aac(3)-IV gene was similar to that in the pAH01-4 plasmid of an Escherichia coli isolate from chicken in China., Conclusion: Resistance to apramycin remains rare in 16S-RMTase-producing isolates. Apramycin may, therefore, be an interesting alternative treatment for infections caused by 16S-RMTase and carbapenemase producers., Competing Interests: Declaration of competing interest None declared, (Copyright © 2023. Published by Elsevier Ltd.)- Published
- 2023
- Full Text
- View/download PDF
15. Multicenter Evaluation of the FilmArray Blood Culture Identification 2 Panel for Pathogen Detection in Bloodstream Infections.
- Author
-
Caméléna F, Péan de Ponfilly G, Pailhoriès H, Bonzon L, Alanio A, Poncin T, Lafaurie M, Dépret F, Cambau E, Godreuil S, Chenouard R, Le Monnier A, Jacquier H, and Berçot B
- Subjects
- Humans, Blood Culture, Bacteria genetics, Gram-Negative Bacteria genetics, Gram-Positive Bacteria, Sepsis diagnosis, Bacteremia diagnosis, Bacteremia microbiology
- Abstract
The FilmArray Blood Culture Identification 2 panel (BCID2; bioMérieux) is a fully automated PCR-based assay for identifying bacteria, fungi, and bacterial resistance markers in positive blood cultures (BC) in about 1 h. In this multicenter study, we evaluated the performance of the BCID2 panel for pathogen detection in positive BC. Conventional culture and BCID2 were performed in parallel at four tertiary-care hospitals. We included 152 positive BC-130 monomicrobial and 22 polymicrobial cultures-in this analysis. The BCID2 assay correctly identified 90% (88/98) of Gram-negative and 89% (70/79) of Gram-positive bacteria. Five bacterial isolates targeted by the BCID2 panel and recovered from five positive BC, including three polymicrobial cultures, were missed by the BCID2 assay. Fifteen isolates were off-panel organisms, accounting for 8% (15/182) of the isolates obtained from BC. The mean positive percent agreement between the BCID2 assay and standard culture was 97% (95% confidence interval, 95 to 99%), with agreement ranging from 67% for Candida albicans to 100% for 17 targets included in the BCID2 panel. BCID2 also identified the bla
CTX-M gene in seven BC, including one for which no extended-spectrum β-lactamase (ESBL)-producing isolate was obtained in culture. However, it failed to detect ESBL-encoding genes in three BC. Two of the 18 mecA/C genes detected by the BCID2 were not confirmed. No carbapenemase, mecA/C , or MREJ targets were detected. The median turnaround time was significantly shorter for BCID2 than for culture. The BCID2 panel may facilitate faster pathogen identification in bloodstream infections. IMPORTANCE Rapid molecular diagnosis combining the identification of pathogens and the detection of antibiotic resistance genes from positive blood cultures (BC) can improve the outcome for patients with bloodstream infections. The FilmArray BCID2 panel, an updated version of the original BCID, can detect 11 Gram-positive bacteria, 15 Gram-negative bacteria, 7 fungal pathogens, and 10 antimicrobial resistance genes directly from a positive BC. Here, we evaluated the real-life microbiological performance of the BCID2 assay in comparison to the results of standard methods used in routine practice at four tertiary care hospitals.- Published
- 2023
- Full Text
- View/download PDF
16. Ceftriaxone-resistant, multidrug-resistant Neisseria gonorrhoeae with a novel mosaic penA-237.001 gene, France, June 2022.
- Author
-
Berçot B, Caméléna F, Mérimèche M, Jacobsson S, Sbaa G, Mainardis M, Valin C, Molina JM, Bébéar C, Chazelle E, Lot F, Golparian D, and Unemo M
- Subjects
- Humans, Female, Neisseria gonorrhoeae, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Multilocus Sequence Typing, Microbial Sensitivity Tests, Drug Resistance, Bacterial genetics, Ceftriaxone pharmacology, Ceftriaxone therapeutic use, Gonorrhea diagnosis, Gonorrhea drug therapy
- Abstract
We report a ceftriaxone-resistant, multidrug-resistant urogenital gonorrhoea case in a heterosexual woman in France, June 2022. The woman was successfully treated with azithromycin 2 g. She had unprotected sex with her regular partner, who developed urethritis following travel to Vietnam and Switzerland. Whole genome sequencing of the gonococcal isolate (F92) identified MLST ST1901, NG-STAR CC-199, and the novel mosaic penA-237.001 , which caused ceftriaxone resistance. penA-237.001 is 98.7% identical to penA-60.001 , reported in various ceftriaxone-resistant strains, including the internationally spreading FC428 clone.
- Published
- 2022
- Full Text
- View/download PDF
17. Detection of Klebsiella pneumoniae isolates coproducing the plasmid-encoded 16S rRNA methyltransferase RmtF and carbapenemase in Paris, France.
- Author
-
Caméléna F, Poncin T, Magnan M, Jacquier H, Merimèche M, and Berçot B
- Subjects
- Anti-Bacterial Agents pharmacology, Bacterial Proteins genetics, Humans, Methyltransferases genetics, Microbial Sensitivity Tests, Paris, Plasmids genetics, RNA, Ribosomal, 16S genetics, beta-Lactamases genetics, Klebsiella Infections, Klebsiella pneumoniae genetics
- Abstract
Competing Interests: Declaration of Competing Interest None declared.
- Published
- 2022
- Full Text
- View/download PDF
18. Clinical performance of four multiplex real-time PCR kits detecting urogenital and sexually transmitted pathogens.
- Author
-
Pereyre S, Caméléna F, Hénin N, Berçot B, and Bébéar C
- Subjects
- Chlamydia trachomatis genetics, Female, Humans, Male, Neisseria gonorrhoeae genetics, Real-Time Polymerase Chain Reaction methods, Ureaplasma, Gonorrhea, Mycoplasma Infections diagnosis, Mycoplasma genitalium genetics, Sexually Transmitted Diseases diagnosis, Sexually Transmitted Diseases microbiology, Trichomonas vaginalis genetics, Urethritis
- Abstract
Objectives: We evaluated the clinical performances of four multiplex real-time PCR commercial kits for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis: the STI PLUS ELITe MGB kit (ELITechGroup), N. gonorrhoeae/C. trachomatis/M. genitalium/T.vaginalis Real-TM kit (Sacace Biotechnologies), Allplex STI Essential kit (Seegene), and FTD Urethritis Plus kit (Fast-Track Diagnostics)., Methods: The kit performance for C. trachomatis, N. gonorrhoeae, M. genitalium and T. vaginalis detection was compared to that of the cobas CT/NG and TV/MG kits (Roche Diagnostics) using 425 samples, mainly urine and cervicovaginal, throat and rectal swabs. Detection of Ureaplasma parvum, U. urealyticum and Mycoplasma hominis were compared to that of in-house TaqMan PCRs., Results: The four kits showed good performances for the detection of C. trachomatis. They all presented a low positive agreement for the detection of M. genitalium and T. vaginalis (ranges 63.3-74.1% and 51.2-68.4%, respectively) compared to the cobas MG/TV kit. The Seegene and Sacace kits showed additional low positive agreement for the detection of N. gonorrhoeae (71.2%, 95%CI 61.8-79.0 and 63.1%, 95%CI 53.5-71.8, respectively). We observed a slight but significant lower negative agreement for N. gonorrhoeae detection using the ELITechGroup kit (92.5%, 89.1-94.9) and for M. genitalium detection using the Fast-Track kit (93.2%, 89.6-95.7) compared to other kits., Conclusion: Multiplex real-time PCR kits are convenient methods for the detection of several pathogens associated with sexually transmitted infections (STIs) in a single step, but colonizing Ureaplasma spp. and M. hominis species should not be included in these kits. Users should be aware of the weak performance of some kits for the detection of M. genitalium and T. vaginalis., (Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
19. Azithromycin Resistance in Shiga Toxin-Producing Escherichia coli in France between 2004 and 2020 and Detection of mef (C)- mph (G) Genes.
- Author
-
Bizot E, Cointe A, Bidet P, Mariani-Kurkdjian P, Hobson CA, Courroux C, Liguori S, Bridier-Nahmias A, Magnan M, Merimèche M, Caméléna F, Berçot B, Weill FX, Lefèvre S, Bonacorsi S, and Birgy A
- Subjects
- Azithromycin pharmacology, Humans, Plasmids genetics, Escherichia coli Infections drug therapy, Escherichia coli Proteins genetics, Shiga-Toxigenic Escherichia coli genetics
- Abstract
We described and characterized Shiga-toxin-producing Escherichia coli (STEC) strains with high levels of resistance to azithromycin isolated in France between 2004 and 2020. Nine of 1,715 (0.52%) STEC strains were resistant to azithromycin, with an increase since 2017. One isolate carried a plasmid-borne mef (C)- mph (G) gene combination, described here for the first time for E. coli. Azithromycin resistance, although rare, needs consideration, as this treatment may be useful in cases of STEC infection.
- Published
- 2022
- Full Text
- View/download PDF
20. Rapid identification of bacteria from respiratory samples of patients hospitalized in intensive care units, with FilmArray Pneumonia Panel Plus.
- Author
-
Caméléna F, Poncin T, Dudoignon E, Salmona M, Le Goff J, Donay JL, Lafaurie M, Darmon M, Azoulay E, Plaud B, Mebazaa A, Dépret F, Jacquier H, and Berçot B
- Subjects
- Adult, Bacteria, Humans, Intensive Care Units, Retrospective Studies, SARS-CoV-2, COVID-19, Pneumonia, Pneumonia, Bacterial diagnosis
- Abstract
Objectives: This study aimed to evaluate the performance of FilmArray Pneumonia Panel Plus (FA-PP) for the detection of typical bacterial pathogens in respiratory samples from patients hospitalized in intensive care units (ICUs)., Methods: FA-PP was implemented for clinical use in the microbiology laboratory in March 2020. A retrospective analysis on a consecutive cohort of adult patients hospitalized in ICUs between March 2020 and May 2020 was undertaken. The respiratory samples included sputum, blind bronchoalveolar lavage (BBAL) and protected specimen brush (PSB). Conventional culture and FA-PP were performed in parallel., Results: In total, 147 samples from 92 patients were analysed; 88% had coronavirus disease 2019 (COVID-19). At least one pathogen was detected in 46% (68/147) of samples by FA-PP and 39% (57/147) of samples by culture. The overall percentage agreement between FA-PP and culture results was 98% (93-100%). Bacteria with semi-quantitative FA-PP results ≥10
5 copies/mL for PSB samples, ≥106 copies/mL for BBAL samples and ≥107 copies/mL for sputum samples reached clinically significant thresholds for growth in 90%, 100% and 91% of cultures, respectively. FA-PP detected resistance markers, including mecA/C, blaCTX-M and blaVIM . The median turnaround time was significantly shorter for FA-PP than for culture., Conclusions: FA-PP may constitute a faster approach to the diagnosis of bacterial pneumonia in patients hospitalized in ICUs., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
21. Bacterial Pneumonia in COVID-19 Critically Ill Patients: A Case Series.
- Author
-
Dudoignon E, Caméléna F, Deniau B, Habay A, Coutrot M, Ressaire Q, Plaud B, Berçot B, and Dépret F
- Subjects
- Critical Illness, Humans, SARS-CoV-2, Anti-Infective Agents, COVID-19, Coinfection, Coronavirus, Pneumonia, Bacterial diagnosis
- Published
- 2021
- Full Text
- View/download PDF
22. Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19.
- Author
-
Caméléna F, Moy AC, Dudoignon E, Poncin T, Deniau B, Guillemet L, Le Goff J, Budoo M, Benyamina M, Chaussard M, Coutrot M, Lafaurie M, Plaud B, Mebazaa A, Depret F, and Berçot B
- Subjects
- Aged, Bacteria classification, Bacteria genetics, Bronchoalveolar Lavage Fluid microbiology, Critical Illness, Female, Humans, Male, Middle Aged, Pneumonia, Bacterial microbiology, SARS-CoV-2, Sensitivity and Specificity, Time Factors, Bacteria isolation & purification, Bacteriological Techniques methods, COVID-19 complications, Multiplex Polymerase Chain Reaction methods, Pneumonia, Bacterial diagnosis
- Abstract
The FilmArray® Pneumonia Plus (FA-PP) panel can provide rapid identifications and semiquantitative results for many pathogens. We performed a prospective single-center study in 43 critically ill patients with coronavirus disease 2019 (COVID-19) in which we performed 96 FA-PP tests and cultures of blind bronchoalveolar lavage (BBAL). FA-PP detected 1 or more pathogens in 32% (31/96 of samples), whereas culture methods detected at least 1 pathogen in 35% (34/96 of samples). The most prevalent bacteria detected were Pseudomonas aeruginosa (n = 14) and Staphylococcus aureus (n = 11) on both FA-PP and culture. The FA-PP results from BBAL in critically ill patients with COVID-19 were consistent with bacterial culture findings for bacteria present in the FA-PP panel, showing sensitivity, specificity, and positive and negative predictive value of 95%, 99%, 82%, and 100%, respectively. Median turnaround time for FA-PP was 5.5 h, which was significantly shorter than for standard culture (26 h) and antimicrobial susceptibility testing results (57 h)., Competing Interests: Competing interests F.C. received conference invitations from BioMérieux., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Rapid Detection and Characterization of Carbapenemases in Enterobacterales with a New Modified Carbapenem Inactivation Method, mCIMplus.
- Author
-
Petit M, Caméléna F, Cointe A, Poncin T, Merimèche M, Bonacorsi S, Birgy A, and Berçot B
- Subjects
- Anti-Bacterial Agents pharmacology, Carbapenems pharmacology, Humans, Bacterial Proteins, beta-Lactamases genetics
- Abstract
The worldwide emergence and spread of antimicrobial resistance in Gram-negative bacteria are severely limiting therapeutic options and thus constitute a major public health threat. The timely accurate detection of carbapenemase producers and the determination of carbapenemase class according to the Ambler classification can guide antimicrobial therapy and facilitate infection control measures. A modified version of the carbapenemase inactivation method (CIM), mCIM, was described and approved by the CLSI in 2017. We evaluated the performance of a faster new mCIM-based assay, mCIMplus, which can detect carbapenemase activity within 8 h and characterize the carbapenemase according to the Ambler classification in 20 h. A panel of 137 isolates producing carbapenemases (GES, IMP, KPC, NDM, OXA-48, OXA-48-like, and VIM enzymes) and 22 non-carbapenemase-producing isolates was used to evaluate the performance of mCIMplus. We evaluated the detection of carbapenemase activity at 8 and 20 h. Carbapenemase class was determined, with specific inhibitors, at 20 h. The sensitivities of mCIMplus were 99.3% at 8 h and 98.5% at 20 h. Its specificity was 100% regardless of culture time. Based on a decision algorithm, this test successfully identified the carbapenemase class for 98.4% of the tested isolates (127/129). Characterization was correct for 100, 95, and 100% of Ambler class A, B, and D isolates, respectively. This test can, therefore, be used to detect carbapenemase activity within 8 h and to determine carbapenemase class within 20 h. It constitutes a very affordable (<€1 per isolate) and reliable technique requiring only basic laboratory equipment., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF
24. Genomic characterization of 16S rRNA methyltransferase-producing Escherichia coli isolates from the Parisian area, France.
- Author
-
Caméléna F, Morel F, Merimèche M, Decousser JW, Jacquier H, Clermont O, Darty M, Mainardis M, Cambau E, Tenaillon O, Denamur E, and Berçot B
- Subjects
- Anti-Bacterial Agents pharmacology, France, Genomics, Methyltransferases genetics, Microbial Sensitivity Tests, Phylogeny, Plasmids genetics, RNA, Ribosomal, 16S genetics, beta-Lactamases genetics, Drug Resistance, Bacterial genetics, Escherichia coli genetics
- Abstract
Background: The resistance to all aminoglycosides (AGs) conferred by 16S rRNA methyltransferase enzymes (16S-RMTases) is a major public health concern., Objectives: To characterize the resistance genotype, its genetic environment and plasmid support, and the phylogenetic relatedness of 16S-RMTase-producing Escherichia coli from France., Methods: We screened 137 E. coli isolates resistant to all clinically relevant AGs from nine Parisian hospitals for 16S-RMTases. WGS was performed on clinical isolates with high-level AG resistance (MIC ≥256 mg/L) and their transformants., Results: Thirty of the 137 AG-resistant E. coli produced 16S-RMTases: 11 ArmA, 18 RmtB and 1 RmtC. The 16S-RMTase producers were also resistant to third-generation cephalosporins (90% due to a blaCTX-M gene), co-trimoxazole, fluoroquinolones and carbapenems (blaNDM and blaVIM genes) in 97%, 83%, 70% and 10% of cases, respectively. Phylogenomic diversity was high in ArmA producers, with 10 different STs, but a similar genetic environment, with the Tn1548 transposon carried by a plasmid closely related to pCTX-M-3 in 6/11 isolates. Conversely, RmtB producers belonged to 12 STs, the most frequent being ST405 and ST complex (STc) 10 (four and four isolates, respectively). The rmtB gene was carried by IncF plasmids in 10 isolates and was found in different genetic environments. The rmtC gene was carried by the pNDM-US plasmid., Conclusions: ArmA and RmtB are the predominant 16S-RMTases in France, but their spread follows two different patterns: (i) dissemination of a conserved genetic support carrying armA in E. coli with high levels of genomic diversity; and (ii) various genetic environments surrounding rmtB in clonally related E. coli., (© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
25. Rapid and Simple Universal Escherichia coli Genotyping Method Based on Multiple-Locus Variable-Number Tandem-Repeat Analysis Using Single-Tube Multiplex PCR and Standard Gel Electrophoresis.
- Author
-
Caméléna F, Birgy A, Smail Y, Courroux C, Mariani-Kurkdjian P, Le Hello S, Bonacorsi S, and Bidet P
- Subjects
- Escherichia coli classification, Escherichia coli genetics, Genotyping Techniques methods, Humans, Minisatellite Repeats, Multilocus Sequence Typing, Bacterial Typing Techniques methods, Electrophoresis, Gel, Pulsed-Field methods, Escherichia coli isolation & purification, Escherichia coli Infections microbiology, Multiplex Polymerase Chain Reaction methods
- Abstract
We developed a multiplex PCR method based on multiple-locus variable-number tandem-repeat (VNTR) analysis (MLVA) that was designed for the rapid typing of Escherichia coli and Shigella isolates. The method amplifies seven VNTRs and does not require a sequencing capillary or fluorescent dyes. The amplification products are simply loaded on a standard agarose gel for electrophoresis, and the banding patterns are analyzed visually. We evaluated the method on 220 strains belonging to different collections: the E. coli reference (ECOR) collection ( n = 72), O1:K1 isolates causing neonatal meningitis ( n = 38), extended-spectrum beta-lactamase-producing fecal isolates belonging to the worldwide sequence type 131 (ST131) clone ( n = 38), Shiga toxin-producing E. coli (STEC) isolates of serogroups O157:H7 ( n = 21) and O26 ( n = 16, 8 of which belonged to an outbreak), 27 Shigella isolates (22 Shigella sonnei isolates, including 5 epidemic strains), and 8 reference strains. The performances were compared to those of multilocus sequence typing (MLST), the DiversiLab automated repetitive element palindromic PCR (REP-PCR), pulsed-field gel electrophoresis (PFGE), and whole-genome sequencing (WGS). We found 66 different profiles among the isolates in the ECOR collection. Among the clonal group O1:K1 isolates, 14 different profiles were identified. For the 37 STEC isolates, we found 23 profiles, with 1 corresponding to the 8 epidemic strains. We found 19 profiles among the 27 Shigella isolates, with 1 corresponding to the epidemic strain. The method was able to recognize strains of the ST131 clone and to distinguish the O16 and O25b serogroups and identified 15 different MLVA types among them. This method allows the simple, fast, and inexpensive typing of E. coli / Shigella isolates that can be carried out in any laboratory equipped for molecular biology and has a discriminatory power superior to that of MLST and DiversiLab REP-PCR but slightly lower than that of PFGE. IMPORTANCE Fast typing methods that can easily and accurately distinguish clonal groups and unrelated isolates are of particular interest for microbiologists confronted with outbreaks or performing epidemiological studies. Highly discriminatory universal methods, like PFGE, optical mapping, or WGS, are expensive and/or time-consuming. MLST is useful for phylogeny but is less discriminatory and requires sequencing facilities. PCR methods, which are fast and easy to perform, also have drawbacks. Random PCRs and REP-PCR are universal but lack reproducibility. Other PCR methods may lack the discriminatory power to differentiate isolates during outbreaks. MLVA combines the advantages of PCR methods with a high discriminatory power but in its standard form requires sequencing capillary electrophoresis. The method that we have developed combines the advantages of standard PCR (simple, fast, and inexpensive) with the high discriminatory power of MLVA and permits the typing of all E. coli isolates (either intestinal or extraintestinal pathogenic isolates as well as commensal isolates)., (Copyright © 2019 American Society for Microbiology.)
- Published
- 2019
- Full Text
- View/download PDF
26. Within-a-Day Detection and Rapid Characterization of Carbapenemase by Use of a New Carbapenem Inactivation Method-Based Test, CIMplus.
- Author
-
Caméléna F, Cointe A, Mathy V, Hobson C, Doit C, Bercot B, Decré D, Podglajen I, Dortet L, Monjault A, Bidet P, Bonacorsi S, and Birgy A
- Subjects
- Anti-Bacterial Agents pharmacology, Bacterial Proteins classification, Bacterial Proteins metabolism, Carbapenem-Resistant Enterobacteriaceae drug effects, Carbapenem-Resistant Enterobacteriaceae enzymology, Carbapenem-Resistant Enterobacteriaceae isolation & purification, Carbapenems pharmacology, Enterobacteriaceae drug effects, Enterobacteriaceae isolation & purification, Enterobacteriaceae Infections diagnosis, Humans, Sensitivity and Specificity, Time Factors, beta-Lactamases classification, beta-Lactamases metabolism, Anti-Bacterial Agents metabolism, Bacterial Proteins analysis, Carbapenems metabolism, Enterobacteriaceae enzymology, Enterobacteriaceae Infections microbiology, Microbial Sensitivity Tests methods, beta-Lactamases analysis
- Abstract
The dissemination of carbapenemase-producing Enterobacteriaceae (CPE) is a major threat to public health. Rapid and accurate detection of CPE is essential for initiating appropriate antimicrobial treatment and establishing infection control measures. The carbapenem inactivation method (CIM), which has good sensitivity and specificity but a detection time of 20 h, was recently described. In this study, we evaluated the performances of a new version, the CIMplus test, which allows detection of carbapenemases in 8 h and characterization of carbapenemase classes, according to the Ambler classification, in 20 h. A panel of 110 carbapenem-resistant Enterobacteriaceae strains, including 92 CPE strains (with NDM, VIM, IMP, KPC, GES, OXA-48, and OXA-48-like enzymes), was used to evaluate test performance. Carbapenemase activity was detected at 8 h and 20 h. Characterization of carbapenemase classes, using specific inhibitors, was possible in 20 h. The CIMplus test had sensitivities of 95.7% and 97.8% at 8 h and 20 h, respectively, and a specificity of 94.4%, independent of the culture duration. Using a decision algorithm, this test was successful in identifying the carbapenemase class for 98.9% of tested CPE isolates (87/88 isolates). In total, the characterization was correct for 100%, 96.9%, and 100% of Ambler class A, B, and D isolates, respectively. Therefore, this test allows detection of carbapenemase activity in 8 h and characterization of carbapenemase classes, according to the Ambler classification, in 20 h. The CIMplus test represents a simple, affordable, easy-to-read, and accurate tool that can be used without any specific equipment., (Copyright © 2018 American Society for Microbiology.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.